<VariationArchive VariationID="206460" VariationName="NM_018129.4(PNPO):c.448_451del (p.Pro150fs)" VariationType="Deletion" Accession="VCV000206460" Version="4" RecordType="classified" NumberOfSubmissions="3" NumberOfSubmitters="3" DateLastUpdated="2024-02-20" DateCreated="2015-08-07" MostRecentSubmission="2024-02-14">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="203481" VariationID="206460">
      <GeneList>
        <Gene Symbol="PNPO" FullName="pyridoxamine 5'-phosphate oxidase" GeneID="55163" HGNC_ID="HGNC:30260" Source="submitted" RelationshipType="within single gene">
          <Location>
            <CytogeneticLocation>17q21.32</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="17" Accession="NC_000017.11" start="47941571" stop="47949308" display_start="47941571" display_stop="47949308" Strand="+" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="17" Accession="NC_000017.10" start="46018888" stop="46026673" display_start="46018888" display_stop="46026673" Strand="+" />
          </Location>
          <OMIM>603287</OMIM>
        </Gene>
      </GeneList>
      <Name>NM_018129.4(PNPO):c.448_451del (p.Pro150fs)</Name>
      <CanonicalSPDI>NC_000017.11:47945887:CTGCCTG:CTG</CanonicalSPDI>
      <VariantType>Deletion</VariantType>
      <Location>
        <CytogeneticLocation>17q21.32</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" forDisplay="true" AssemblyStatus="current" Chr="17" Accession="NC_000017.11" start="47945888" stop="47945891" display_start="47945888" display_stop="47945891" variantLength="4" positionVCF="47945887" referenceAlleleVCF="ACTGC" alternateAlleleVCF="A" />
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="17" Accession="NC_000017.10" start="46023254" stop="46023257" display_start="46023254" display_stop="46023257" variantLength="4" positionVCF="46023253" referenceAlleleVCF="ACTGC" alternateAlleleVCF="A" />
      </Location>
      <ProteinChange>P150fs</ProteinChange>
      <HGVSlist>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000017.10" sequenceAccession="NC_000017" sequenceVersion="10" change="g.46023257_46023260del" Assembly="GRCh37">
            <Expression>NC_000017.10:g.46023257_46023260del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh38" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000017.11" sequenceAccession="NC_000017" sequenceVersion="11" change="g.47945891_47945894del" Assembly="GRCh38">
            <Expression>NC_000017.11:g.47945891_47945894del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_008744.1" sequenceAccession="NG_008744" sequenceVersion="1" change="g.9369_9372del">
            <Expression>NG_008744.1:g.9369_9372del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_018129.4" sequenceAccession="NM_018129" sequenceVersion="4" change="c.448_451del" MANESelect="true">
            <Expression>NM_018129.4:c.448_451del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_060599.1" sequenceAccession="NP_060599" sequenceVersion="1" change="p.Pro150fs">
            <Expression>NP_060599.1:p.Pro150fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
      </HGVSlist>
      <XRefList>
        <XRef ID="CA208971" DB="ClinGen" />
        <XRef Type="rs" ID="796052872" DB="dbSNP" />
      </XRefList>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NM_018129.4(PNPO):c.448_451del (p.Pro150fs) AND not provided" Accession="RCV000188508" Version="1">
        <ClassifiedConditionList TraitSetID="9460">
          <ClassifiedCondition DB="MedGen" ID="C3661900">not provided</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2014-11-07" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_018129.4(PNPO):c.448_451del (p.Pro150fs) AND Pyridoxal phosphate-responsive seizures" Accession="RCV000194659" Version="4">
        <ClassifiedConditionList TraitSetID="1807">
          <ClassifiedCondition DB="MedGen" ID="C1864723">Pyridoxal phosphate-responsive seizures</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2023-09-19" SubmissionCount="2">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2023-09-19" NumberOfSubmissions="3" NumberOfSubmitters="3" DateCreated="2015-08-07" MostRecentSubmission="2024-02-14">
        <ReviewStatus>criteria provided, multiple submitters, no conflicts</ReviewStatus>
        <Description>Pathogenic</Description>
        <Citation Type="general">
          <ID Source="PubMed">15772097</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">24645144</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">28349276</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">29588952</ID>
        </Citation>
        <DescriptionHistory Dated="2020-04-24">
          <Description>Pathogenic/Likely pathogenic</Description>
        </DescriptionHistory>
        <ConditionList>
          <TraitSet ID="9460" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="17556" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">not provided</ElementValue>
                <XRef ID="13DG0619" DB="Department Of Translational Genomics (developmental Genetics Section), King Faisal Specialist Hospital &amp; Research Centre" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">none provided</ElementValue>
              </Name>
              <AttributeSet>
                <Attribute Type="public definition">The term 'not provided' is registered in MedGen to support identification of submissions to ClinVar for which no condition was named when assessing the variant. 'not provided' differs from 'not specified', which is used when a variant is asserted to be benign, likely benign, or of uncertain significance for conditions that have not been specified.</Attribute>
              </AttributeSet>
              <XRef ID="C3661900" DB="MedGen" />
            </Trait>
          </TraitSet>
          <TraitSet ID="1807" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="5840" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Pyridoxal phosphate-responsive seizures</ElementValue>
                <XRef ID="MONDO:0012407" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Pyridoxamine 5-Prime-Phosphate Oxidase Deficiency</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">EPILEPTIC ENCEPHALOPATHY, NEONATAL, PNPO-RELATED</ElementValue>
                <XRef Type="MIM" ID="610090" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">SEIZURES, PYRIDOXINE-RESISTANT, PLP-SENSITIVE</ElementValue>
                <XRef Type="MIM" ID="610090" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Pyridoxal 5'-phosphate-dependent epilepsy</ElementValue>
                <XRef ID="Pyridoxal+5%27-phosphate-dependent+epilepsy/9199" DB="Genetic Alliance" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Pyridoxine-5'-phosphate oxidase deficiency</ElementValue>
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">PNPOD</ElementValue>
                <XRef Type="MIM" ID="610090" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="disease mechanism" integerValue="273">loss of function</Attribute>
                <XRef ID="GTR000500548" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000506564" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000552389" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000508374" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000551668" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000514632" DB="Genetic Testing Registry (GTR)" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">Untreated pyridox(am)ine 5'-phosphate oxidase (PNPO) deficiency, characterized by a range of seizure types, is "classic" (i.e., seizure onset in the neonatal period) in about 90% of affected individuals and "late onset" (seizure onset after the neonatal period) in about 10%. In classic PNPO deficiency, seizures (including status epilepticus) often begin on the first day of life and typically before age two weeks. In both classic and late-onset untreated PNPO deficiency, seizure semiology varies from myoclonic to clonic or tonic seizures, and seizures are typically resistant to common anti-seizure medications. Independent of age of onset, seizures respond to life-long treatment with a B6 vitamer: pyridoxal 5'-phosphate (PLP) in about 60% of affected individuals and pyridoxine (PN) in about 40%. About 60% of individuals with PNPO deficiency have developmental impairment, affecting speech, cognition, and behavior; some individuals have neurologic impairment such as muscular hypotonia or dystonia. Severe neurodevelopmental impairment is more likely to occur in individuals with PNPO deficiency who experienced diagnostic delay and prolonged periods of uncontrolled seizures.</Attribute>
                <XRef ID="NBK581452" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="10730" />
                <XRef ID="10730" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">35737815</ID>
                <ID Source="BookShelf">NBK581452</ID>
              </Citation>
              <XRef ID="79096" DB="Orphanet" />
              <XRef ID="C1864723" DB="MedGen" />
              <XRef ID="MONDO:0012407" DB="MONDO" />
              <XRef Type="MIM" ID="610090" DB="OMIM" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="446860" SubmissionDate="2015-07-30" DateLastUpdated="2015-08-07" DateCreated="2015-08-07">
        <ClinVarSubmissionID localKey="49236" />
        <ClinVarAccession Accession="SCV000242122" DateUpdated="2015-08-07" DateCreated="2015-08-07" Type="SCV" Version="3" SubmitterName="GeneDx" OrgID="26957" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2014-11-07">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Comment>c.448_451delCCTG: p.Pro150ArgfsX27 in exon 5 in the PNPO gene (NM_018129.3). The normal sequence with the bases that are deleted in braces is: ACTG{CCTG}AGGA. The maternally inherited c.448_451delCCTG mutation in the PNPO gene has not been reported previously as a disease-causing mutation nor as a benign polymorphism, to our knowledge. The c.448_451delCCTG mutation causes a frameshift starting with codon Proline 150, changes this amino acid to a Arginine residue and creates a premature Stop codon at position 27 of the new reading frame, denoted p.Pro150ArgfsX27. This mutation is predicted to cause loss of normal protein function either through protein truncation or nonsense-mediated mRNA decay. The c.448_451delCCTG mutation was not observed in approximately 6,500 individuals of European and African American ancestry in the NHLBI Exome Sequencing Project, indicating it is not a common benign variant in these populations. We interpret c.448_451delCCTG as a disease-causing mutation. This variant has been observed to be maternally inherited The variant is found in PNPO, panel(s).</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">GeneDx Variant Classification (06012015)</Attribute>
          <Citation Type="general">
            <URL>https://submit.ncbi.nlm.nih.gov/ft/byid/dhtz9flo/genedx_interprules_final_061215.pdf</URL>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>yes</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="PNPO" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <OtherNameList>
            <Name>p.P150RfsX27</Name>
          </OtherNameList>
          <AttributeSet>
            <Attribute Type="HGVS">NM_018129.3:c.448_451delCCTG</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">not provided</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
      </ClinicalAssertion>
      <ClinicalAssertion ID="461255" SubmissionDate="2015-05-29" DateLastUpdated="2015-10-05" DateCreated="2015-10-05">
        <ClinVarSubmissionID localKey="NM_018129.3:c.448_451delCCTG|OMIM:610090" />
        <ClinVarAccession Accession="SCV000223944" DateUpdated="2015-10-05" DateCreated="2015-10-05" Type="SCV" Version="1" SubmitterName="Knight Diagnostic Laboratories, Oregon Health and Sciences University" OrgID="505542" OrganizationCategory="laboratory" OrgAbbreviation="KDL-OHSU" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2015-03-12">
          <ReviewStatus>no assertion criteria provided</ReviewStatus>
          <GermlineClassification>Likely pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="ModeOfInheritance">Autosomal recessive inheritance</Attribute>
        </AttributeSet>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>no</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="PNPO" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <Location>
            <GeneLocation>NM_018129.3:exon 5</GeneLocation>
          </Location>
          <OtherNameList>
            <Name>p.Pro150Argfs*27</Name>
          </OtherNameList>
          <AttributeSet>
            <Attribute Type="HGVS">NM_018129.3:c.448_451delCCTG</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">Pyridoxal 5'-phosphate-dependent epilepsy</ElementValue>
            </Name>
            <XRef DB="OMIM" ID="610090" Type="MIM" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>NextGen Project</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="4147690" SubmissionDate="2024-02-08" DateLastUpdated="2024-02-14" DateCreated="2022-03-28">
        <ClinVarSubmissionID localKey="3789391|MedGen:C1864723" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV002129545" DateUpdated="2024-02-14" DateCreated="2022-03-28" Type="SCV" Version="3" SubmitterName="Invitae" OrgID="500031" OrganizationCategory="laboratory" OrgAbbreviation="Invitae" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2023-09-19">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">15772097</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">24645144</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">28349276</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">29588952</ID>
          </Citation>
          <Comment>This sequence change creates a premature translational stop signal (p.Pro150Argfs*27) in the PNPO gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in PNPO are known to be pathogenic (PMID: 15772097, 24645144). This variant is present in population databases (rs775105142, gnomAD 0.02%). This premature translational stop signal has been observed in individual(s) with clinical features of pyridoxal 5'-phosphate-dependent epilepsy (PMID: 28349276, 29588952). ClinVar contains an entry for this variant (Variation ID: 206460). For these reasons, this variant has been classified as Pathogenic.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Invitae Variant Classification Sherloc (09022015)</Attribute>
          <Citation>
            <ID Source="PubMed">28492532</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="PNPO" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000017.10:g.46023254_46023257del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C1864723" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB11173117</SubmissionName>
          <SubmissionName>SUB12507860</SubmissionName>
          <SubmissionName>SUB14200283</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="461255" TraitType="Disease" MappingType="Name" MappingValue="Pyridoxal 5'-phosphate-dependent epilepsy" MappingRef="Preferred">
        <MedGen CUI="C1864723" Name="Pyridoxal phosphate-responsive seizures" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="446860" TraitType="Disease" MappingType="Name" MappingValue="not provided" MappingRef="Preferred">
        <MedGen CUI="C3661900" Name="not provided" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="4147690" TraitType="Disease" MappingType="XRef" MappingValue="C1864723" MappingRef="MedGen">
        <MedGen CUI="C1864723" Name="Pyridoxal phosphate-responsive seizures" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

